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EXTRAORDINARY CASE REPORT
Specific Skin Infiltration as First Sign of Localized Stage
Hodgkin’s Lymphoma Involving an Epitrochlear Node
Mar Llamas-Velasco, MD, Javier Fraga, MD, PhD,* Silvia Pérez-Gala, MD,† Jimena Cannata, MD,‡
Werner Kempf, MD, PhD,†§ Magdalena Adrados, MD, PhD,* and Amaro García-Diez, MD, PhD†
Abstract: Cutaneous manifestation as the ﬁrst sign of Hodgkin
lymphoma (HL) is very rare and diagnostically challenging;
especially, because the clinical presentation of speciﬁc skin involve-
ment by HL is polymorphous. We present a 44-year-old man with
erythematous indurate papules and plaques in the right forearm and
arm where skin biopsy showed an HL. He also has an enlarged
epitrochlear node, and later histopathologic study conﬁrmed the
diagnosis of HL subtype–mixed cellularity. Immunohistochemical
stains in both biopsies showed that the atypical cells were positive
for CD30 and CD15, and negative for CD20 and CD3. PAX5 stained
the nuclei of the atypical large lymphoid cells weakly and Oct-2
staining was negative in the atypical cells. EBER and LMP1 protein
were negative in both biopsies. Epitrochlear involvement in HL, like
in our case, is a rare event (,1%). We reviewed data about progno-
sis, clinical appearance, and treatment of all the cases of HL speciﬁc
skin involvement published after Sioutos et al, emphasizing the cases
where HL speciﬁc skin involvement was the ﬁrst sign of the disease
as in our patient.
(Am J Dermatopathol 2014;0:1–4)
INTRODUCTION
Nonspeciﬁc cutaneous manifestations of Hodgkin dis-
ease/lymphoma (HL) are quite frequent,1,2 with 17%–53% of
patients developing any of them2,3 but the incidence of spe-
ciﬁc cutaneous HL varies between only 0.5% and 7.5%.3
Cutaneous manifestation as the ﬁrst sign of HL is very rare
and diagnostically challenging; especially, because the clini-
cal presentation of speciﬁc skin involvement by HL is poly-
morphous. The most common ones are papular or nodular
lesions.1,4 We report a patient with speciﬁc skin involvement
by HL as the ﬁrst disease presentation of a localized HL
involving an epitrochlear lymph node and lacking association
with Epstein–Barr virus (EBV).
CASE REPORT
A 44-year-old white man with no contributory medical history
complained of a plaque on the lateral aspect of forearm that appeared
a year earlier. Five months later, similar papules and plaques have
progressively appeared on his ipsilateral arm. All lesions were stable
and asymptomatic. The patient denied other skin or mucosal lesions,
fevers, chills, weight loss, or other systemic symptoms. On physical
examination, he presented with an erythematous indurated plaque of
1.7 · 2 cm on the right forearm and several similar smaller papular
lesions on his right arm with a sporotrichoid pattern (Fig. 1A). A
mobile and consistent epitrochlear ipsilateral enlarged lymph node
with 2 cm was found (Fig. 1B). A skin biopsy showed a dense
nodular inﬁltration by lymphocytes and histiocytes, and scattered
eosinophils arranged throughout the dermis. Those cells were mixed
with large lymphoid cells with hyperchromatic and irregularly
shaped nuclei representing Reed–Sternberg cells (Figs. 2A, B). An
epitrochlear lymph node biopsy demonstrated features of classic HL
of mixed cellularity subtype in the interfollicular region (Figs. 3A,
B). Immunohistochemical stains in both biopsies showed that the
atypical cells were positive for CD30 and CD15, and negative for
CD20 and CD3 (Figs. 2C, D, 3C, D). PAX5 stained the nuclei of the
atypical large lymphoid cells weakly and Oct-2 staining was nega-
tive in the atypical cells (Fig. 4). EBER and LMP1 protein were
negative in both biopsies. ALK staining was negative in node.
Viral serologies were negative for HIV but positive for EBV.
A computed tomography examination of the thorax, abdomen, and
pelvis disclosed axillary enlarged lymph nodes. Examination of the
bone marrow was normal. He was diagnosed with HL at Cotswolds
stage IIAE and treated with 6 cycles of ABVD regimen (doxorubicin,
bleomycin, vinblastine, and dacarbazine), which resulted in a com-
plete remission. The patient was disease-free after a follow-up of
38 months.
DISCUSSION
We had reviewed the literature on HL speciﬁc skin
involvement, and we found 20 articles reporting 26 cases
including ours1,3,5–22 in the last decade because we agree with
other authors who consider the cases described by Sioutus et
al as the ﬁrst well-deﬁned cases of HL speciﬁc to skin
involvement. All the cases of HL speciﬁc to skin involvement
as the ﬁrst sign of the disease as in our patient can be seen in
Table 1. We did not include series without reporting HL stage
or individual data of the patients.
In the rest of the reported cases, HL speciﬁc to skin
involvement was a sign of relapse of a previously known HL.
Primary cutaneous HL is exceedingly rare and only a few
well-documented cases have claimed this diagnosis,5,6,9,12,14,15
some of them with lately systemic involvement. Within these
cases, three of the cases reported by Sioutos et al could be
more accurately considered lymphomatoid papulosis because
of their waxing and waning chronic clinical course.
Related to prognosis, skin speciﬁc involvement in HL is
considered in most of the reports as a prognostically
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unfavorable sign indicating a stage IV. In our review, 8 of the
18 cases of HL speciﬁc skin involvement as the ﬁrst sign of
disease presented with III or IV stages but only 2 deaths were
reported. Only one additional death was added from the rest
of the cases. Unfortunately, immunohistochemistry panels
cannot differentiate primary and secondary cutaneous HL,23
and the literature review indicates that it is not possible to
determine whether the course of the disease in patients with
HL with skin involvement, primary or not, will be severe or
mild.4 Recently, new markers as paired box gene 5 (PAX5),
FIGURE 1. A, Indurated, lobulated
erythematous plaques with well-
defined borders and sporotricoid
pattern located in the right arm and
forearm. B, Epitrochlear enlarge
node.
FIGURE 2. A, Hematoxylin and
eosin (HE), ·10. Nodular infiltrates
with a granulomatous pattern. B,
HE, ·20. Lymphocytes, histiocytes,
and eosinophils mixed with big cells
with basophilic cytoplasm and 2 or
bigger nuclei with patent eosino-
philic nucleoli can be identified as
Reed–Sternberg cells. C–E, CD15
and CD30 positivity of the Reed–
Sternberg cells and Reed–Sternberg
cells rimmed by T cells with CD3
immunostaining.
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octamer-binding transcription factor-2 (Oct-2), and B-cell
Oct-binding protein 1 (BOB-1) have been described to dem-
onstrate B-cell lineage of HD24 and to exclude histopatho-
logic mimickers. PAX5 staining in cutaneous HD is weaker
in the large atypical nuclei compared with the surrounding
reactive B cells as in our case, and it helped to exclude
a CD15+ anaplastic large cell lymphoma.23 Negative staining
for CD20 and Oct-2 and the weak staining of PAX5 also
argue against a B-cell non-HL.
The distribution of the lesions in our patient conﬁrms to
the most frequently reported mechanism of skin involvement;
by HL that is in proximity to the involved lymph nodes
because of retrograde lymphatic spread. Both direct extension
from an underlying affected node and hematogenous dissem-
ination have been also described.12
Epitrochlear involvement in HL, like in our case, is
a rare event (,1%), although it has similar prognosis to that
of other HL locations if appropriately treated.25
Finally, in North America and western Europe,
30%–50% of HL is associated with EBV, with a rate of
up to 90% in mixed cellularity subtype.6 There are several
cases of EBER and LMP1 positive HL6,12 that strongly
favor HL diagnosis over CD30+ lymphoproliferative dis-
orders.6 The lack of association with EBV in our patient is
an infrequent feature of HL,6 and is particularly diagnos-
tically challenging in separating HL from cutaneous
CD30+ lymphoproliferative disorders. The lack of sponta-
neous regression of the lesions in our case argues against
lymphomatoid papulosis. The phenotype of the large atyp-
ical CD30+ cells in our patient with weak expression of the
B-cell marker Pax5 and detection of nodal HL excludes the
diagnosis of a primary cutaneous anaplastic large-cell
lymphoma.
In summary, our case is noteworthy because skin
lesions were the ﬁrst site of presentation and skin biopsy
led to the diagnosis of HL, although our case is rather
a secondary HL with nodal epithrochlear involvement.
Although cutaneous HL is rare, especially in localized stages,
and the prevalence of speciﬁc secondary cutaneous HL seems
to be diminishing, probably because of the advent of better
therapy,3 clinicians and pathologists should be aware of this
rare manifestation of HL that ﬁrst presents in the skin to
identify early underlying HL. In addition, epitrochlear lymph
node involvement has not been previously reported in patients
with HL with skin involvement.
FIGURE 3. A, Focal infiltrates of
epithelioid histiocytes, eosinophils,
and plasma cells. B, Large atypical
mono- and bi-nucleated cells, some
with Reed–Sternberg cells, charac-
teristics can be observed. C, CD15
staining and CD30 staining. D, Inset:
CD30 positivity of a Hodgkin and
a Reed–Sternberg cell.
FIGURE 4. PAX 5 staining showing positivity in enlarged
atypical lymphocytes.
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TABLE 1. Reported Skin Involvement as First Sign of HL in the Last 10 years
Author
Age/
Gender, yr Clinic Location Node/Megaly Stage Treatment Response
Our case 44/M P and Pl R. forearm Epithroclear IIE AVBD CR after 38 m
Vieites et al15 74/M N Scalp None IE Lomustina, etoposide,
prednisone
CR after 10 m
Pranteda et al14 10/M P and N R. back None IE RT CR after 20 mo
Hsia et al13 54/M Ulcerated Pl L. gluteal area Generalized IIIB AVBD CR
Khalifeh et al12 67/M Solitary Pl Occipital Paraesophageal and
bronchopulmonary/none
IV AVBD PR
Mukesh et al11 59/M P and Pl Flank, feet, inner
R. thigh
None IE AVBD CR after 3 yrs
Balighi et al18 15/M Ulcerated Pl B. Axillar Generalized/splenomegaly IV COPP CR after 9 mo
Miyoshi et al10 44/M N L. lower back Paraaortic/
hepatosplenomegaly
IV Etoposide, ifosfamide,
vindesine + electron beam
No response, death 5 mo
later
Erkiliç et al22 25/F, Ulcer Neck Generalized/splenomegaly
(both)
IIIBE EBVD CR after 2 yrs
19/F Subcutaneous
mass
Neck Generalized/splenomegaly
(both)
IIIBE ABVD CR after 3 yrs
De Grip et al20 34/F Sinus Neck Tracheoesophageal ﬁstula III/IV Unknown Unknown
Guitart and
Fretzin9
86/M T L. ankle None/none IIB RT No response, death in few
months
Takagawa
et al7
71/M N Supraclavicular area Left supraclavicular/none IV Surgery and COPP CR
Sioutos et al5 54/M N L. leg None IE RT CR for 6 yrs
52/M T and P R. forearm None IE None RL
17/M N Trunk None IE Topical CT RL
50/M N R. thigh None IE MOPP-ABVD CR
45/F N Forearm and legs None IE Multiple chemotherapy CR
Clinic—N, Nodules; P, papules; Pl, plaques; T, Tumor.
Location—B, Both; L, Left; R, Right.
Treatment—AVBD: Adriamycin, vinblastine, bleomycin, dacarbazine; COPP: cyclophosphamide, vincristine, procarbazina, prednisolone; CT, corticosteroids; RT, radiotherapy.
Response—CR, complete response; PR, partial response; RL, recurrent lesions.
EBVD, epirubicin, bleomycin, vinblastine and dacarbazine; MOPP, mechlorethamine, vincristine, procarbazine, prednisone.
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